Your browser doesn't support javascript.
loading
Predictors of mortality in inflammatory bowel disease patients treated for pneumonia.
Ukashi, Offir; Barash, Yifatch; Segel, Michael J; Ungar, Bella; Soffer, Shelly; Ben-Horin, Shomron; Klang, Eyal; Kopylov, Uri.
Afiliação
  • Ukashi O; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Ha'ela 1, Ramat-Gan 526560, Israel.
  • Barash Y; Sackler School of Medicine, Tel-Aviv University, Israel.
  • Segel MJ; Sackler School of Medicine, Tel-Aviv University, Israel.
  • Ungar B; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel.
  • Soffer S; Sackler School of Medicine, Tel-Aviv University, Israel.
  • Ben-Horin S; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel.
  • Klang E; Sackler School of Medicine, Tel-Aviv University, Israel.
  • Kopylov U; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel.
Therap Adv Gastroenterol ; 13: 1756284820939453, 2020.
Article em En | MEDLINE | ID: mdl-32821289
ABSTRACT

BACKGROUND:

Community-acquired pneumonia is among the most common infections affecting ulcerative colitis and Crohn's disease patients. Data regarding epidemiology and outcomes of pneumonia in inflammatory bowel disease patients is lacking. We aimed to identify predictors of adverse outcomes among inflammatory bowel disease patients treated for pneumonia.

METHODS:

This was a retrospective cohort study that included adult patients admitted to Sheba Medical Center for pneumonia between 2012 and 2018. Data was collected from an electronic repository of all emergency department admissions and included tabular demographic and clinical variables and free-text physician records. Pneumonia cases were extracted using the International Classification of Diseases (ICD-10) coding.

RESULTS:

Of 16,732 admissions with pneumonia, 97 were inflammatory bowel disease patients (45 Crohn's disease; 52 ulcerative colitis). We found a similar rate of 30-day mortality among inflammatory bowel disease and non-inflammatory bowel disease patients (12.1% versus 11.3%, p = 0.824) and between Crohn's disease and ulcerative colitis patients (11.1% versus 11.5%, p = 0.947). There was an increased hospitalization rate among inflammatory bowel disease patients (92.8% versus 85.6%, p = 0.045), but similar hospitalization duration (4 versus 4 days, p = 0.384). Crohn's disease patients had a shorter hospitalization duration compared with ulcerative colitis patients (3 versus 5.5 days, p = 0.029). Bronchiectasis (adjusted odds ratio 60.95, 95% confidence interval 2.72-1364.39, p = 0.01) and opioids use (adjusted odds ratio 13.21, 95% confidence interval 1.29-135.18, p = 0.03) were associated with an increased 30-day mortality rate in inflammatory bowel disease patients.

CONCLUSION:

This is the first study to identify predictors of mortality in inflammatory bowel disease patients with pneumonia. The rate of mortality and hospitalization duration of stay were similar among inflammatory bowel disease and non-inflammatory bowel disease patients. Use of opioids and presence of bronchiectasis were associated with a higher risk of mortality in inflammatory bowel disease patients with pneumonia.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article